ML 348 (Synonyms: CID 3238952, SID 160654487) |
Catalog No.GC18039
One-Click Copy Product Info
|
ML 348 is a selective and reversible lysophospholipase 1 (LYPLA1) inhibitor with an IC50 of approximately 210nM, exhibiting 14-fold selectivity for LYPLA1 over LYPLA2.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 899713-86-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
ML 348 is a selective and reversible lysophospholipase 1 (LYPLA1) inhibitor with an IC50 of approximately 210nM, exhibiting 14-fold selectivity for LYPLA1 over LYPLA2[1-2]. ML 348 can be used to study protein palmitoylation and the biological functions of LYPLA1, and it significantly inhibits enzymatic activity in heart, lung, and kidney tissues[3-4].
In vitro, pretreatment of porcine alveolar macrophages (PAMs) with ML 348 (1μM) for 24–36 hours, followed by infection with porcine reproductive and respiratory syndrome virus (PRRSV-2; MOI=0.1), significantly suppressed viral ORF7 mRNA transcription and nucleocapsid protein (N protein) expression, while reducing viral titers[5]. Pretreatment of NRAS-mutant melanoma cells with ML 348 (≤12.5μM) for 6 hours did not significantly affect cell viability and did not markedly inhibit phosphorylation of the NRAS downstream signaling pathways ERK and AKT[6].
In vivo, chronic subcutaneous infusion of ML 348 (0.3mg/kg) for 28 days in 7-month-old symptomatic CAG140 Huntington's disease knock-in mice effectively crossed the blood-brain barrier, significantly improved motor coordination and alleviated anxiety-depressive-like behaviors, and reversed neuropathological changes[7]. Oral administration of ML 348 (70mg/kg) for 90 days in 12-month-old symptomatic 3KL α-synucleinopathy model mice significantly enhanced motor coordination, spatial memory, and long-term memory, and restored hippocampal synaptic plasticity[8].
References:
[1] Adibekian A, Martin BR, Chang JW, et al. Characterization of a Selective, Reversible Inhibitor of Lysophospholipase 1 (LYPLA1). National Center for Biotechnology Information (US); 2010- 2013 Apr 08.
[2] Hulce JJ, Joslyn C, Speers AE, et al. An in Vivo Active Carbamate-based Dual Inhibitor of Lysophospholipase 1 (LYPLA1) and Lysophospholipase 2 (LYPLA2). National Center for Biotechnology Information (US); 2013 Dec 9.
[3] Won SJ, Davda D, Labby KJ, et al. Molecular Mechanism for Isoform-Selective Inhibition of Acyl Protein Thioesterases 1 and 2 (APT1 and APT2). ACS Chem Biol. 2016 Dec 16;11(12):3374-3382.
[4] Gu M, Jiang H, Tan M, et al. Palmitoyltransferase DHHC9 and acyl protein thioesterase APT1 modulate renal fibrosis through regulating β-catenin palmitoylation. Nat Commun. 2023 Oct 21;14(1):6682.
[5] Jing H, Liu Y, Song Y, et al. ZDHHC3-LYPLA1 regulates PRRSV-2 replication through reversible palmitoylation. Vet Microbiol. 2025 Feb;301:110368.
[6] Vujic I, Sanlorenzo M, Esteve-Puig R, et al. Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells. Oncotarget. 2016 Feb 9;7(6):7297-306.
[7] Virlogeux A, Scaramuzzino C, Lenoir S, et al. Increasing brain palmitoylation rescues behavior and neuropathology in Huntington disease mice. Sci Adv. 2021 Mar 31;7(14):eabb0799.
[8] Moors TE, Li S, McCaffery TD, et al. Increased palmitoylation improves estrogen receptor alpha-dependent hippocampal synaptic deficits in a mouse model of synucleinopathy. Sci Adv. 2023 Nov 15;9(46):eadj1454.
| Cell experiment [1]: | |
Cell lines | NRAS mutant melanoma cells |
Preparation Method | Cells were treated with ML 348 (≤12.5µM) for 6 hours to assess acute signaling changes. |
Reaction Conditions | ≤12.5μM; 6h |
Applications | ML 348 caused minor increases in AKT phosphorylation but did not alter ERK or S6 phosphorylation, indicating no biologically significant impact on NRAS downstream signaling pathways. |
| Animal experiment [2]: | |
Animal models | CAG140 knock-in HD mice (Huntington disease model) |
Preparation Method | Mice were subcutaneously infused with ML 348 (0.3mg/kg/day) via Alzet osmotic pumps for 28 days. Behavioral tests and tissue analyses were conducted during and after treatment. |
Dosage form | 0.3mg/kg; subcutaneous infusion; Chronic administration; Daily for 28 days. |
Applications | ML 348 treatment restored motor coordination in the horizontal ladder test (reduced error rate and crossing time), improved balance in rotarod tests, and alleviated anxio-depressive behaviors in novelty-suppressed feeding tests. ML 348 increased brain palmitoylation levels, reduced mutant huntingtin (mHTT) nuclear accumulation, and restored corticostriatal synapse density. |
References: | |
| Cas No. | 899713-86-1 | SDF | |
| Synonyms | CID 3238952, SID 160654487 | ||
| Chemical Name | N-(2-chloro-5-(trifluoromethyl)phenyl)-2-(4-(furan-2-carbonyl)piperazin-1-yl)acetamide | ||
| Canonical SMILES | ClC1=C(NC(CN2CCN(C(C3=CC=CO3)=O)CC2)=O)C=C(C(F)(F)F)C=C1 | ||
| Formula | C18H17ClF3N3O3 | M.Wt | 415.79 |
| Solubility | ≥ 19.1mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4051 mL | 12.0253 mL | 24.0506 mL |
| 5 mM | 481 μL | 2.4051 mL | 4.8101 mL |
| 10 mM | 240.5 μL | 1.2025 mL | 2.4051 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 31 reference(s) in Google Scholar.)